Clinical Trial

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

Study acronym: KRdvsRd
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new standard for elderly newly diagnosed multiple myeloma (NDMM) patients. The combination carfilzomib plus lenalidomide-dexamethasone (KRd) in relapsed-refractory MM patients improved the progression-free survival (PFS) of approximately 1 year compared to standard Rd treatment. In a small phase 2 trial (23 pts) the KRd combination in elderly NDMM pts showed a complete response (CR) rate of 79% and a PFS at 3 years of 80%. Cardiovascular adverse events are the most limiting toxicities, especially in elderly patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-09-17; most recent amendment 2025-01-14.
Status change: Recruiting → Active, Not Recruiting 2023-09-29
Trial Details
NCT Number NCT04096066
Lead Sponsor Fondazione EMN Italy Onlus
Conditions Multiple Myeloma, New Diagnosis Tumor
Enrollment 84 participants
Start Date 2019-07-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-15